منابع مشابه
Cabazitaxel (Jevtana)
440 P&T® • August 2012 • Vol. 37 No. 8 ABSTRACT Objective: This article presents current clinical evidence supporting the use of cabazitaxel (Jevtana) in men with metastatic castration-resistant prostate cancer (mCRPC). Data Sources: We conducted a literature search using abstracts from MEDLINE and PubMed (from January 1966 to December 2011) and the American Society of Clinical Oncology (from J...
متن کاملPreclinical profile of cabazitaxel
First-generation taxanes have changed the treatment paradigm for a wide variety of cancers, but innate or acquired resistance frequently limits their use. Cabazitaxel is a novel second-generation taxane developed to overcome such resistance. In vitro, cabazitaxel showed similar antiproliferative activity to docetaxel in taxane-sensitive cell lines and markedly greater activity in cell lines res...
متن کاملMechanisms of resistance to cabazitaxel.
We studied mechanisms of resistance to the novel taxane cabazitaxel in established cellular models of taxane resistance. We also developed cabazitaxel-resistant variants from MCF-7 breast cancer cells by stepwise selection in drug alone (MCF-7/CTAX) or drug plus the transport inhibitor PSC-833 (MCF-7/CTAX-P). Among multidrug-resistant (MDR) variants, cabazitaxel was relatively less cross-resist...
متن کاملCabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Introduction Cabazitaxel is a new member of the taxane group and is not crossresistant with docetaxel. In vitro it has been shown to promote tubulin assembly and also to stabilize microtubules against depolymerization as successfully as docetaxel. Cabazitaxel has recently been shown to improve survival in patients with prostate cancer who have previously been treated with docetaxel. We report t...
متن کاملCabazitaxel: a new drug for metastatic prostate cancer.
I n Western countries, prostate cancer is the most common malignancy in men and ranks third in mortality. In 2010, an estimated 217 730 new cases are anticipated in the United States, and about 32 050 men are expected to die from the disease. Until 2004, numerous clinical trials in men with metastatic castration-resistant prostate cancer (mCRPC) failed to demonstrate any significant change in o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Biology & Therapy
سال: 2010
ISSN: 1538-4047,1555-8576
DOI: 10.4161/cbt.10.12.14085